NYSE:BHVNBiotechs
Biohaven (BHVN): Evaluating Valuation After UBS Downgrade and Shifting Analyst Sentiment
Biohaven (BHVN) is in the spotlight after UBS downgraded its rating and revised its outlook. Other firms have made similar changes as well. These shifts in analyst sentiment can impact investor confidence and trading activity.
See our latest analysis for Biohaven.
Biohaven’s share price has seen sharp swings lately, rising 5.8% in a single day but still down more than 41% for the month and over 73% year-to-date. Despite some lively trading sessions and high-profile analyst downgrades, the...